Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer

  title={Figitumumab combined with carboplatin and paclitaxel in treatment-na{\"i}ve Japanese patients with advanced non-small cell lung cancer},
  author={Yasushi Goto and Ikuo Sekine and Maki Tanioka and Takashi Shibata and Chiharu Tanai and Hajime Asahina and Hiroshi Nokihara and Noboru Yamamoto and Hideo Kunitoh and Yuichiro Ohe and Hironori Kikkawa and Emiko Ohki and Tomohide Tamura},
  booktitle={Investigational New Drugs},
Objectives The insulin-like growth factor (IGF) signaling pathway has been implicated in the pathogenesis of numerous tumor types, including non-small cell lung cancer (NSCLC). Figitumumab is a fully human IgG2 monoclonal antibody against IGF-1 receptor (IGF-1R). Methods This phase I, open-label, dose-escalation study ( NCT00603538) assessed the safety and tolerability of figitumumab (6, 10 and 20 mg/kg) in combination with carboplatin (area under the curve: 6 mg·min/mL) and… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 19 extracted citations


Publications referenced by this paper.
Showing 1-10 of 24 references

Phase I study of MK0646, a humanized monoclonal antibody against IGF-IR in combination with gemcitabine or gemcitabine plus erlotinib for advanced previously untreated pancreatic cancer

  • M Javle, GR Varahachary, +5 authors JL Abbruzzese
  • Poster presented at the 2010 American Society of…
  • 2010

Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC)

  • J Jassem, CJ Langer, +7 authors A Gualberto
  • J Clin Oncol 28(15s) (abstr
  • 2010
2 Excerpts

Similar Papers

Loading similar papers…